Point72 Asset Management
VKTX icon

Point72 Asset Management’s Viking Therapeutics VKTX Stock Holding History

Point72 Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$618K Buy
19,000
+12,100
+175% +$389K ﹤0.01% 3030
2025
Q4 		$243K Buy
+6,900
New +$244K ﹤0.01% 3564
2023
Q2 		– Sell
-300,000
Closed -$5M – 2819
2023
Q1 		$5M Buy
+300,000
New +$3.1M 0.02% 754

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Point72 Asset Management's VKTX Position: Q1 2026 in Review

Point72 Asset Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 313,492 shares — an estimated $10.1M sold.

Point72 Asset Management first reported a position in VKTX in Q4 2022 and held it in 6 quarters. The position peaked at $18.2M in Q1 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Point72 Asset Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 313,492 Viking Therapeutics shares in Q1 2026, an estimated $10.1M.
  • Point72 Asset Management first reported a position in Viking Therapeutics in Q4 2022 and held it in 6 quarters.
  • Point72 Asset Management's Viking Therapeutics position peaked at $18.2M in Q1 2023.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.